Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Genesis’s TCM Flu Treatment Approved by SFDA

publication date: Jul 15, 2008

Genesis Pharmaceuticals Enterprises was granted SFDA approval for Radix Isatidis Dispersible Tablets. Radix Isatidis is a very popular traditional Chinese medicine used to treat the flu, though it was previously available only as a powder, which is dissolved in hot water. The Genesis formulation is the only dispersible tablet available. As a whole, Radix Isatidis is a $1.4 billion market annually. Genesis forecasts that it will manufacture and sell somewhere between $4 million and $10 million of its product in the next fiscal year (which ends June 30, 2009). More details...

Stock Symbol: (OTCBB: GTEC)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital